CSTB Gene, Repeat Expansion Analysis, Varies
Use
This test is useful for the molecular confirmation of clinically suspected CSTB-related progressive myoclonic epilepsy. It identifies full penetrance dodecamer repeat expansions within CSTB known to cause CSTB-related progressive myoclonic epilepsy, allowing for predictive testing of at-risk family members. The test impacts patient treatment and management by identifying a specific underlying etiology for epilepsy, directing appropriate use of anti-epileptic drugs and other treatment modalities.
Special Instructions
For predictive testing, it is important to first document the molecular etiology of disease in an affected family member. A test request should include an informed consent for genetic testing for New York clients. Additional maternal cell contamination studies are recommended for postnatal umbilical cord whole blood specimens.
Limitations
This assay will not detect nonrepeat expansion variants, and progressive myoclonic epilepsy may be caused by variants in other genes. Rare variants may lead to false-negative results. The test results should be interpreted in the context of clinical findings, family history, and other laboratory data.
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 41110-8
- 50397-9
- 82939-0
- 69047-9
- 42349-1
- 31208-2
- 85069-3
- 18771-6
Result Turnaround Time
14-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
Not provided
Container
Lavender top (EDTA), yellow top (ACD), or green top (sodium heparin)
Collection Instructions
Invert several times to mix blood. Send whole blood specimen in original tube. Do not aliquot.
Patient Preparation
A previous hematopoietic stem cell transplant from an allogenic donor will interfere with testing.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |
| Frozen | 4 days |
